Evaxion Biotech As Stock Performance
| EVAX Stock | USD 2.63 0.02 0.75% |
Evaxion Biotech holds a performance score of 15 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 1.75, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Evaxion Biotech will likely underperform. Use Evaxion Biotech coefficient of variation, semi variance, period momentum indicator, as well as the relationship between the treynor ratio and daily balance of power , to analyze future returns on Evaxion Biotech.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Evaxion Biotech AS are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Evaxion Biotech showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
Five Day Return (5.40) | Year To Date Return (43.07) | Ten Year Return (99.47) | All Time Return (99.47) |
Last Split Factor 1:5 | Last Split Date 2025-01-14 |
1 | Evaxion Biotech AS Announces Key Resolutions from April 2025 AGM - TipRanks | 05/05/2025 |
2 | Evaxion AS Q1 2025 Earnings Call Highlights Strong Cash Position and Promising Vaccine ... | 05/28/2025 |
3 | Zacks Small Cap Analysts Reduce Earnings Estimates for EVAX | 05/29/2025 |
4 | Evaxion receives grant funding to design new polio vaccine EVAX Stock News | 06/03/2025 |
5 | Evaxion expands RD pipeline with new vaccine program targeting Group A Streptococcus | 06/25/2025 |
6 | Evaxion AS Upgraded at Wall Street Zen | 06/30/2025 |
7 | Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology platform and portfolio | 07/01/2025 |
8 | Evaxion Secures Equity Boost Through Debt Conversion EVAX Stock News | 07/11/2025 |
9 | Evaxion Biotech Finalizes Debt Settlement with EIB - TipRanks | 07/17/2025 |
| Begin Period Cash Flow | 5.6 M | |
| Total Cashflows From Investing Activities | -3000.00 |
Evaxion Biotech Relative Risk vs. Return Landscape
If you would invest 131.00 in Evaxion Biotech AS on April 20, 2025 and sell it today you would earn a total of 132.00 from holding Evaxion Biotech AS or generate 100.76% return on investment over 90 days. Evaxion Biotech AS is currently generating 1.3445% in daily expected returns and assumes 6.7056% risk (volatility on return distribution) over the 90 days horizon. In different words, 60% of stocks are less volatile than Evaxion, and 73% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Evaxion Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Evaxion Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Evaxion Biotech AS, and traders can use it to determine the average amount a Evaxion Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2005
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | EVAX | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.71 actual daily | 60 60% of assets are less volatile |
Expected Return
| 1.34 actual daily | 27 73% of assets have higher returns |
Risk-Adjusted Return
| 0.2 actual daily | 15 85% of assets perform better |
Based on monthly moving average Evaxion Biotech is performing at about 15% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Evaxion Biotech by adding it to a well-diversified portfolio.
Evaxion Biotech Fundamentals Growth
Evaxion Stock prices reflect investors' perceptions of the future prospects and financial health of Evaxion Biotech, and Evaxion Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Evaxion Stock performance.
| Return On Equity | -2.06 | ||||
| Return On Asset | -0.37 | ||||
| Operating Margin | (4.31) % | ||||
| Current Valuation | 21.09 M | ||||
| Shares Outstanding | 6.32 M | ||||
| Price To Book | 1.55 X | ||||
| Price To Sales | 5.08 X | ||||
| Revenue | 3.34 M | ||||
| Gross Profit | 3.29 M | ||||
| EBITDA | (9.77 M) | ||||
| Net Income | (10.55 M) | ||||
| Cash And Equivalents | 25.25 M | ||||
| Cash Per Share | 1.06 X | ||||
| Total Debt | 10.1 M | ||||
| Debt To Equity | 0.48 % | ||||
| Current Ratio | 6.47 X | ||||
| Book Value Per Share | 1.87 X | ||||
| Cash Flow From Operations | (12.94 M) | ||||
| Earnings Per Share | (12.00) X | ||||
| Market Capitalization | 16.74 M | ||||
| Total Asset | 12.48 M | ||||
| Retained Earnings | (118.54 M) | ||||
| Working Capital | 4.4 M | ||||
About Evaxion Biotech Performance
Evaluating Evaxion Biotech's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Evaxion Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Evaxion Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -1.4 K | -1.5 K | |
| Return On Tangible Assets | (0.85) | (0.89) | |
| Return On Capital Employed | (1.81) | (1.72) | |
| Return On Assets | (0.85) | (0.89) | |
| Return On Equity | 6.40 | 6.72 |
Things to note about Evaxion Biotech AS performance evaluation
Checking the ongoing alerts about Evaxion Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Evaxion Biotech AS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Evaxion Biotech AS is way too risky over 90 days horizon | |
| Evaxion Biotech AS appears to be risky and price may revert if volatility continues | |
| Evaxion Biotech AS has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 3.34 M. Net Loss for the year was (10.55 M) with profit before overhead, payroll, taxes, and interest of 3.29 M. | |
| Evaxion Biotech AS currently holds about 25.25 M in cash with (12.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.06. | |
| Evaxion Biotech AS has a frail financial position based on the latest SEC disclosures | |
| Roughly 23.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Evaxion Biotech Finalizes Debt Settlement with EIB - TipRanks |
- Analyzing Evaxion Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Evaxion Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Evaxion Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Evaxion Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Evaxion Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Evaxion Biotech's stock. These opinions can provide insight into Evaxion Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Evaxion Stock Analysis
When running Evaxion Biotech's price analysis, check to measure Evaxion Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evaxion Biotech is operating at the current time. Most of Evaxion Biotech's value examination focuses on studying past and present price action to predict the probability of Evaxion Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evaxion Biotech's price. Additionally, you may evaluate how the addition of Evaxion Biotech to your portfolios can decrease your overall portfolio volatility.